Tenderwize
Wróć do wyszukiwania

Framework contracts for innovative infectious disease therapeutics

Health and Digital Executive Agency (HaDEA)·Brussels, Belgium·EUR 252M·Deadline Sep 02, 2026 · 10 days left·Neg W Call·Services·Framework
Zarejestruj się, aby zapisaćOpen documents
High value
Oryginalny tytuł ogłoszenia

Belgium – Research and development services and related consultancy services – Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

75/100

Ocena szansy

PromisingHigh complexity
ServicesFrameworkOpen
Skąd ta ocena?

Szansa

75 / 100

Złożoność

85 / 100

Czynniki ryzyka

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 10 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • EUR 252M estimated value
  • Framework procurement
  • Services contract
  • 2 lots
  • Lot 1: Development of pathogen-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
  • Lot 2: Development of host-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
Pokaż pełne podsumowanie

This Pre-Commercial Procurement (PCP) call, led by the Health and Digital Executive Agency (HaDEA), aims to accelerate the development of innovative medical countermeasures for infectious diseases, specifically next-generation therapeutics. The tender consists of two lots: 'Highly Innovative Therapeutics' (Lot 1, value €138M) focusing on pathogen-targeted scalable therapeutics, and 'Advanced Therapeutics' (Lot 2, value €114M) focusing on host-targeted scalable therapeutics. Both lots include combination therapies and alternative IV routes. The overall estimated value is €252M, funded under EU4Health. The procedure is a negotiated procedure with call for competition, resulting in multiple sourcing framework contracts. Evaluation is 80% quality and 20% price. Submission deadline: 2026-09-02.

Ryzyka

Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...

Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.

Submission deadline in 10 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must address viral infections, ARDS, or sepsis resulting from infections.
  • Pathogen-targeted therapeutics (Lot 1) or host-targeted therapeutics (Lot 2).
  • Excludes small molecules, monoclonal antibodies; includes direct/indirect antivirals, immune modulators.

Kryteria udzielenia

Lot 1

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Lot 2

Quality criterion with weight 80% (per-exa). — 80%Price criterion with weight 20% (per-exa). — 20%

Zamawiający

Lokalizacja

Brussels, BEL

Identyfikator

HADEA

Działalność

General public services

Części (2)

LOT-0001

Highly Innovative Therapeutics

Lot 1 targets pathogen-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Szacowana wartość

Czas trwania

108 MONTH

Kategoria

Research

Kryteria udzielenia

Best price-quality ratio

Termin

Deadline Sep 02, 2026

LOT-0002

Advanced Therapeutics

Lot 2 targets host-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.

ServicesFrameworkEU fundedElectronic submission

EUR 252M

Szacowana wartość

Czas trwania

69 MONTH

Kategoria

Research

Kryteria udzielenia

Best price-quality ratio

Termin

Deadline Sep 02, 2026

Szczegóły zamówienia

Data publikacji
01 Jul 2026
Języki
English, Bulgarian

Metadane referencyjne

Podstawa prawna
32024R2509

Identyfikatory referencyjne

ID przetargu
456593-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Spain – Research and experimental development services – Pre-commercial Procurement of an innovative Systemic Sustainability Transition Solution for Health Care Organisations (suHCO)

Oct 9

France – Research and experimental development services – Chambre d’essais pour des tests en Compatibilité Electro-Magnétique (CEM) d’équipements fonctionnant à l’hydrogène

Aug 25

Belgium – Research and experimental development services – Long-term API stockpiling and rapid finished dose form manufacture

Sep 21

Norway – Research and development services and related consultancy services – Preventive conversations as a means of the police ́s preventive work.

Sep 8

Germany – Research and experimental development services – Toolkit für aktives Verteilnetzmanagement

Aug 31

Norway – Research and development services and related consultancy services – Evaluation of the police's national efforts against criminal networks.

Sep 10